These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24231212)

  • 1. Possible function of urinary pH and citrate on the ceftriaxone-induced nephrolithiasis.
    Cong X; Gu X; Sun X; Ning B; Shen L
    Urology; 2014 Jan; 83(1):63-7. PubMed ID: 24231212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftriaxone crystallization and its potential role in kidney stone formation.
    Chutipongtanate S; Thongboonkerd V
    Biochem Biophys Res Commun; 2011 Mar; 406(3):396-402. PubMed ID: 21329669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium oxalate crystallization in undiluted postprandial urine of healthy male volunteers as influenced by citrate.
    Fan J; Schwille PO; Schmiedl A; Fink E; Manoharan M
    Arzneimittelforschung; 2001 Oct; 51(10):848-57. PubMed ID: 11715639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alkaline citrate in prevention of recurrent calcium oxalate stones.
    Berg C
    Scand J Urol Nephrol Suppl; 1990; 130():1-83. PubMed ID: 2291093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citrate, malate and alkali content in commonly consumed diet sodas: implications for nephrolithiasis treatment.
    Eisner BH; Asplin JR; Goldfarb DS; Ahmad A; Stoller ML
    J Urol; 2010 Jun; 183(6):2419-23. PubMed ID: 20403610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Escherichia coli on urine citrate and urease-induced crystallization.
    Edin-Liljegren A; Hedelin HH; Grenabo L; Pettersson S
    Scanning Microsc; 1995 Sep; 9(3):901-5. PubMed ID: 7501998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
    Hassani MA; Hennequin C; Lacour B; Daudon M
    Prog Urol; 2005 Sep; 15(4):650-5. PubMed ID: 16459680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The change of human Na+/dicarboxylate co-transporter 1 expression in the kidney and its relationship with pathogenesis of nephrolithiasis].
    He Y; Chen X; Yu Z
    Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(17):1066-9. PubMed ID: 11758258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of citrate in patients with nephrolithiasis].
    Marangella M
    G Ital Nefrol; 2017 Aug; 34(4):51-60. PubMed ID: 28762682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of citrate on the different phases of calcium oxalate crystallization.
    Tiselius HG; Berg C; Fornander AM; Nilsson MA
    Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary stone formers with hypocitraturia and 'normal' urinary pH are at high risk for recurrence.
    Strohmaier WL; Seilnacht J; Schubert G
    Urol Int; 2012; 88(3):294-7. PubMed ID: 22398801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nephrolithiasis in patients with intestinal diseases].
    Cirillo M; Iudici M; Marcarelli F; Laudato M; Zincone F
    G Ital Nefrol; 2008; 25(1):42-8. PubMed ID: 18264917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis.
    Marangella M; Bagnis C; Bruno M; Vitale C; Petrarulo M; Ramello A
    Urol Int; 2004; 72 Suppl 1():6-10. PubMed ID: 15133325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine citrate and renal stone disease.
    Goldberg H; Grass L; Vogl R; Rapoport A; Oreopoulos DG
    CMAJ; 1989 Aug; 141(3):217-21. PubMed ID: 2665909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body size and 24-hour urine composition.
    Taylor EN; Curhan GC
    Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Citrate and kidney stones].
    Osther PJ
    Ugeskr Laeger; 1993 Nov; 155(47):3835-9. PubMed ID: 8256384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of urine pH and citrate concentration on the upper limit of metastability for calcium phosphate.
    Greischar A; Nakagawa Y; Coe FL
    J Urol; 2003 Mar; 169(3):867-70. PubMed ID: 12576801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.